Patients with primary glioma, WHO grade IV glioma, and recurrent glioma in whom SOCS3 expression levels were higher than the median consistently demonstrated unfavorable OS rates compared with those with lower-than-median SOCS3 expression levels (Figure 5). Here, SOCS3 is linked to central nervous system cancer.